Objective: To test the hypothesis that insulin detemir, which is associated with less weight gain than other basal insulin formulations, exerts its weight-modulating effects by acting on brain regions involved in appetite regulation, as represented by altered cerebral blood flow (CBF) or cerebral glucose metabolism (CMRglu).
Research Design And Methods: Twenty-eight male type 1 diabetic patients (age 36.9 ± 9.